Quoin Pharmaceuticals, Ltd. American Depositary Shares

Day range

$3.96 – $4.19

Open

$3.96

Prev close

$4.02

Volume

1.77K

Market cap

$19.31M

Shares out

3.12M

P/E

—

P/S

—

P/B

4.91

P/FCF

—

ROE

-474.6%

ROA

-155.9%

Debt/Equity

0.29

Div yield

0.00%

As of Oct 23, 2026

• Clinical trial resultsOct 20, 2026

  “Separately, in August Quoin reported positive interim results from CL-QRX003-004, its ongoing Phase 2/3 study of QRX003 4% lotion in Netherton Syndrome. In the interim analysis of the first six participants to complete 12 weeks of treatment, four of six (66.7%) achieved the primary endpoint of a 1-grade or greater improvement in Investigator Global Assessment (p=0.0087 vs. a pre-specified alpha of 0.0215).”

• Regulatory decisionOct 14, 2026

  “QRX003 has been granted Orphan Drug Designation in Europe by the European Medicines Agency (the ‘EMA’) for the treatment of Peeling Skin Syndrome.”

• Regulatory decisionSep 22, 2026

  On September 22, 2026, the Company announced that the FDA has granted Fast Track Designation to the Company's lead asset, QRX003, for the treatment of Peeling Skin Syndrome.

• Regulatory decisionSep 10, 2026

  On September 8, 2026, the Company announced that the FDA has granted Rare Pediatric Disease (RPD) Designation for the Company's lead asset, QRX003, for the treatment of Peeling Skin Syndrome (PSS).

• Clinical trial resultsAug 28, 2026

  On August 28, 2026, the Company announced positive interim results from CL-QRX003-004, its ongoing Phase 2/3 study of QRX003 4% lotion in patients with Netherton Syndrome. For the first six participants to complete 12 weeks of treatment, the study met its primary endpoint with statistical significance. Four of six (66.7%) participants achieved the target 1-grade or greater improvement across all of the treatment area in Investigator Global Assessment (IGA) from baseline at Week 12, or 66.67% (95% CI: 22.28%, 95.67%), p=0.0087 against a pre-specified alpha of 0.0215.

Days to cover

1.4

Short interest

65.47K

Avg volume

47.42K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Quoin (QNRX) Q2 Loss Beats Estimates
  neutralThe Motley Fool· Aug 8, 2025
• PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials
  positiveGlobeNewswire Inc.· Jan 7, 2025
• Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference
  GlobeNewswire Inc.· Jun 25, 2024
• Quoin Pharmaceuticals Announces Signing of Research Agreement with University College Cork (UCC), Ireland
  GlobeNewswire Inc.· Jun 12, 2024
• Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024
  GlobeNewswire Inc.· May 2, 2024